ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02652455
Recruitment Status : Active, not recruiting
First Posted : January 11, 2016
Last Update Posted : December 4, 2018
Sponsor:
Collaborators:
Bristol-Myers Squibb
Prometheus Inc.
Iovance Biotherapeutics, Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:

The purpose of this Pilot Study is to investigate the safety, side effects, and benefits of tumor- infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

The primary endpoints of this pilot trial will be the safety and feasibility of the treatment regimens.


Condition or disease Intervention/treatment Phase
Melanoma (Skin) Skin Cancer Drug: Nivolumab Procedure: Surgery to Remove Tumor for Growth of TIL Drug: CD137 Drug: Cyclophosphamide Drug: Fludarabine Biological: TIL Infusion Drug: Interleukin-2 Early Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Actual Study Start Date : March 2, 2016
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: PD-1, CD137 and Adoptive Cell Therapy

Combination Therapy and Immunotherapy as described in intervention descriptions.

  1. Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
  2. Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment.
Drug: Nivolumab
Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
Other Names:
  • Opdivo
  • PD-1 blocking antibody
  • BMS-936558

Procedure: Surgery to Remove Tumor for Growth of TIL
All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
Other Names:
  • Tumor Infiltrating Lymphocytes (TILs)
  • T-cell

Drug: CD137
All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
Other Names:
  • anti-CD137 agonistic antibody
  • BMS-663513
  • 4-1BB

Drug: Cyclophosphamide
All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
Other Name: Cytoxan

Drug: Fludarabine
All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
Other Name: Fludara

Biological: TIL Infusion
After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.

Drug: Interleukin-2
After TIL infusion, in-patient high dose IL-2 treatment.
Other Names:
  • IL-2
  • Proleukin
  • Aldesleukin




Primary Outcome Measures :
  1. Occurrence of Study Related Adverse Events [ Time Frame: Up to 27 months ]
    Safety will be determined by assessing toxicity based upon Common Terminology Criteria for Adverse Events (CTCAE) v4.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have unresectable cutaneous or mucosal metastatic stage III/IV melanoma, and in the opinion of the institutional principal investigator (PI) is an acceptable candidate for adoptive cell therapy (ACT) with high dose IL-2. Patients with mucosal metastatic melanoma may be included, as our prior experience indicates that TIL can be successfully propagated from these subtypes of melanoma metastases.
  • Must have anticipated residual measurable disease after resection of target lesion(s) for TIL growth.
  • Patients who have been previously treated for metastatic melanoma may be included (e.g., prior treatment with Rapidly Accelerated Fibrosarcoma (BRAF) inhibitors and/or ipilimumab will be allowed), provided that they have had a three week 'washout' prior to signing consent and have not been treated with a Programmed Death-1 (PD-1) blocking antibody.
  • Age greater than or equal to 18 years.
  • Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1.
  • Women of childbearing potential must have a negative serum pregnancy test within seven days of screening and within 24 hours prior to the start of each nivolumab dose.
  • Adequate renal, hepatic and hematologic function.
  • Patients must have a positive screening Epstein Barr Virus (EBV) antibody titer on screening test as this is required to protect against EBV infection during the time of lymphodepletion.
  • Patients with antibiotic allergies per se are not excluded; although the production of TIL for adoptive transfer includes antibiotics, extensive washing after harvest will minimize systemic exposure to antibiotics.
  • At screening, patients with ≤ 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (MRI or CT if MRI is contraindicated), and if the patients with CNS metastases are not taking prednisone >10 mg or equivalent daily.
  • At screening, patients with ≤ 3 CNS metastases and each ≤ 1 cm size that were treated with either surgical resection and/or radiation therapy may be included. Patients may be included if the largest lesion is ≤ 1 cm, and there is no evidence of progressive CNS disease on brain imaging at least 30 days after definitive treatment, and if the patients with CNS metastases are not taking prednisone >10 mg or equivalent daily.
  • At screening, patients with> 1 cm or > 3 in number treated CNS metastases may be included if there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy, and if the patients with CNS metastases are not taking prednisone >10 mg or equivalent daily.

Exclusion Criteria:

  • Patients with active systemic infections requiring intravenous antibiotics, coagulation disorders, or other major medical illness of the cardiovascular, respiratory or immune system, which in the opinion of the PI or treating co-investigator is not acceptable risk for ACT, are excluded.
  • Patients who have received prior immunotherapy whose side effects have resulted in a requirement of immunosuppressive medications (>10 mg of prednisone daily or equivalent daily steroid daily, or infliximab, cyclosporine or equivalent immunosuppressive medication) or who have other autoimmune conditions that require immunosuppressive medications as above at the time of screening are excluded.
  • Patients who test positive for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, Hepatitis B core antibody, Hepatitis C antibody, Human T-lymphotropic Virus (HTLV) I or II antibody, or are both Rapid plasma reagin (RPR) and Fluorescent treponemal antibody (FTA) positive are excluded.
  • Patients who are pregnant or nursing are excluded.
  • Patients with a significant psychiatric disease, who in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe will be excluded.
  • Patients with > 3 untreated CNS metastases or evidence of peri-tumoral edema will be excluded, or patients with CNS metastases of any status who are taking prednisone >10 mg or equivalent steroid daily will be excluded.
  • Patients with ≤ 3 untreated CNS metastases but with at least one lesion >1 cm or peri-tumoral edema will be excluded, or patients with CNS metastases of any status who are taking prednisone >10 mg or equivalent steroid daily will be excluded.
  • Patients with invasive malignancy other than melanoma at the time of enrollment and within 2 years of screening are excluded, except for: adequately treated (i.e. with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other any other cancers from which the patient has been disease-free for at least 2 years.
  • Patients with treated CNS metastases > 1 cm or > 3 in number will be excluded if there is evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy, or patients with CNS metastases of any status who are taking prednisone >10 mg or equivalent will be excluded.
  • Male patients with female partners of childbearing potential who do not agree to use two FDA-accepted forms of contraception during sexual intercourse with women of child-bearing potential from the start of PD-1 antibody therapy and up to at least 31 weeks from the last dose of nivolumab are excluded.
  • Females of childbearing potential who do not agree to use 2 FDA forms of contraception according to study guidelines
  • Prior systemic therapy with a PD-1 blocking antibody
  • Patients who are greater than age 50, or who have a history of coronary artery disease, will be required to undergo cardiac stress testing within 6 months of screening and will be excluded if there is evidence of reversible ischemia.
  • Patients who have a significant history of pulmonary disease that necessitates the use of supplemental oxygen, is associated with dyspnea on walking one block or less, or requires inhaler therapy more than once per week will be required to undergo pulmonary function testing within 6 months of screening and will be excluded if forced expiratory volume 1 (FEV1), forced vital capacity (FVC), or diffusion lung capacity for carbon monoxide (DLCO) is less than 65% of predicted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652455


Locations
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Prometheus Inc.
Iovance Biotherapeutics, Inc.
Investigators
Principal Investigator: Amod Sarnaik, M.D. H. Lee Moffitt Cancer Center and Research Institute

Additional Information:
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT02652455     History of Changes
Other Study ID Numbers: MCC-18377
First Posted: January 11, 2016    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: December 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
cutaneous
unresectable
mucosal metastatic stage III/IV melanoma

Additional relevant MeSH terms:
Melanoma
Skin Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site
Skin Diseases
Cyclophosphamide
Fludarabine phosphate
Nivolumab
Fludarabine
Interleukin-2
Antibodies
Immunoglobulins
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Analgesics, Non-Narcotic